The HEDGEHOG-GLI (HH-GLI) signalling is a key pathway critical in embryonic development, stem cell biology and tissue homeostasis. In recent years, aberrant activation of HH-GLI signalling has been linked to several types of cancer, including those of the skin, brain, lungs, prostate, gastrointestinal tract and blood. HH-GLI signalling is initiated by binding of HH ligands to the transmembrane receptor PATCHED and is mediated by transcriptional effectors that belong to the GLI family, whose activity is finely tuned by a number of molecular interactions and post-translation modifications. Several reports suggest that the activity of the GLI proteins is regulated by several proliferative and oncogenic inputs, in addition or independent of upstream HH signalling. The identification of this complex crosstalk and the understanding of how the major oncogenic signalling pathways interact in cancer is a crucial step towards the establishment of efficient targeted combinatorial treatments. Here we review recent findings on the cooperative integration of HH-GLI signalling with the major oncogenic inputs and we discuss how these cues modulate the activity of the GLI proteins in cancer. We then summarise the latest advances on SMO and GLI inhibitors and alternative approaches to attenuate HH signalling through rational combinatorial therapies.
Introduction
The HEDGEHOG-GLI (HH-GLI) signalling plays a critical role in embryonic development, stem cell biology and tissue homeostasis, cellular metabolism, synapse formation and nociception (Refs 1, 2, 3, 4, 5). Aberrant activation of the HH signalling has been linked to different aspects of cancer development, from initiation to metastasis (Ref.6) .CanonicalHHpathwayactivationisinitiated by the binding of HH ligands to the transmembrane receptor PATCHED (PTCH), which relieves its inhibition on the transmembrane protein SMOOTHENED (SMO). Consequently, active SMO triggers an intracellular signalling cascade leading to the formation of activator forms of the GLI zinc finger transcription factors GLI2 and GLI3, which directly induce GLI1. Both GLI1 and GLI2 act as main mediators of HH signalling in cancer by controlling the expression of target genes.
Recent evidence suggests that GLI proteins can be directly and indirectly modulated by proliferative and oncogenic inputs, in addition or independent of upstream HH signalling. These mechanisms of aberrant, non-canonical HH-GLI pathway activation, apparently without known driver mutations in components of the pathway, have been associated with several types of human cancer (Ref. 7) . In this review, we focus on the cooperative interaction between HH-GLI and other oncogenic signalling pathways. We first address the functions and post-translational modifications of the three GLI transcription factors, and the mechanisms that regulate their activity in cancer. We then review latest advances on SMO and GLI inhibitors and discuss approaches to attenuate HH signalling through rational combinatorial therapies.
Overview of the HEDGEHOG-GLI signalling
The Hh signalling has been initially identified in Drosophila melanogaster, where it is required for determining proper embryonic patterning (Ref. 8) . Smo protein is conserved and maintains its function in mammals, whereas there are two Ptch proteins in vertebrates. Hh ligand has diversified into Sonic (SHH), Indian (IHH) and Desert (DHH) Hedgehog, and the function of the downstream transcription factor Cubitus interruptus (Ci) has evolved into three GLI proteins: GLI1, GLI2 and GLI3. Here we focus on the function and regulation of the three GLI transcription factors and we present only a brief introduction of the key steps and components of vertebrate HH-GLI signalling upstream of GLI. The initiation of the HH signalling begins with the binding of one of the three HH ligands, each with distinct spatial and temporal expression patterns, to the 12-pass transmembrane protein receptor PTCH, which resides in the primary cilium, a non-motile structure that functions as a sensor and coordinator centre for the HH signalling (Refs 9, 10, 11). Binding of HH ligands to PTCH relieves its inhibitory effect on the G-protein-coupled receptor-like SMO, which moves into the tip of the cilium and triggers a cascade of events that promote the formation of GLI activator forms (GLI-A). GLI2/3-A translocate into the nucleus and induce HH pathway target genes, including GLI1 (Refs 12, 13, 14) (Fig. 1) . In absence of HH ligands, PTCH inhibits pathway activation by preventing SMO to enter the cilium. This results in the phosphorylation and proteasome-mediated carboxyl cleavage of GLI3 and, to a lesser extent, of GLI2 to their repressor forms (GLI2/3-R; Refs 15, 16) . GLI1 is degraded by the proteasome and is transcriptionally repressed, with consequent silencing of the pathway. GLI1 acts exclusively as an activator, whereas GLI2 and GLI3 display both positive and negative transcriptional functions (Refs 15, 17, 18) ( Fig. 1) .
The HH target genes include GLI1, which further amplifies the initial HH signalling at transcriptional level and, therefore, is a reliable and robust read-out of an active pathway (Ref. 19) . Other HH target genes are PTCH1 and HH interacting protein (HHIP1), which both mediate negative feedback by limiting the extent of HH signalling. The outcome of the HH signalling varies according to the receiving cell type, and includes a number of cell-specific targets mediating a variety of cellular responses: proliferation and differentiation (Cyclin D1 and D2, E2F1, N-Myc, FOXM1, PDGFRα, IGFBP3 and IGFBP6, Hes1, Neogenin), cell survival (BCL-2), self-renewal (Bmi1, Nanog, Sox2), angiogenesis (Vegf, Cyr61), cardiomyogenesis (MEF2C), epithelial-mesenchymal transition (Snail1, Sip1, Elk1 and Msx2) and invasiveness (Osteopontin). (Ref. 20) . The strength of HH signalling is tuned by a number of posttranscriptional and post-translational modifications of the three GLI transcription factors.
The GLI transcription factors and their modifications
The three GLI transcription factors are members of the Kruppel family. They share five conserved C 2 -H 2 zinc-finger DNA-binding domains and a consensus histidine/cysteine linker sequence between the zinc fingers, and bind to the consensus motif GACCACCCA in the promoter of their target genes (Ref. 21) . The sequence specificity of the GLI transcription factors, although, is not absolute, because they can recognise variant GLI-binding sites with relatively low affinity, still leading to strong transcriptional transactivation (Ref. 22) .
GLI1 is a transcriptional target of GLI2 and GLI3 (Refs 17, 23) and a strong transcriptional activator. In both human and mouse cells, GLI1 protein is Key components of the mammalian HH signaling pathway Figure 1 . Key components of the mammalian HH signalling pathway. In absence of HH ligands (a), PTCH inhibits SMO by preventing its entry into the primary cilium. GLI proteins are phosphorylated by PKA, GSK3β and CK1, which create binding sites for the E3 ubiquitin ligase β-TrCP. GLI3 and, to a lesser extent, GLI2 undergo partial proteasome degradation, leading to the formation of repressor forms (GLI3/2 R , red), that translocate into the nucleus where they inhibit the transcription of HH target genes. Full-length GLI may also be completely degraded by the proteasome. This process can be mediated by Spop and Cullin 3-based E3 ligase for GLI2 and GLI3, whereas GLI1 can be degraded by β-TrCP, the Numb-activated Itch E3 ubiquitin ligase and by PCAF (see text for details). Upon HH ligand binding (b), PTCH is displaced from the primary cilium, allowing accumulation and activation of SMO. Active SMO promotes a signalling cascade that ultimately leads to translocation of full length (FL) activated forms of GLI (GLI A , green) into the nucleus, where they induce transcription of HH target genes. Abbreviations: CK1, casein kinase 1; GSK3β, glycogen synthase kinase 3β; HH, Hedgehog; PCAF, p300/CREB-binding protein (CBP)-associated factor; PKA, protein kinase A; PTCH, Patched; SMO, Smoothened; Spop, speckle-type POZ protein; SUFU, Suppressor of Fused; β-TrCP, β-transducin repeat-containing protein.
at position 2179. The consequent arginine-toglycine amino acidic change at position 701 produces a GLI1 protein less sensitive to the inhibitory effect of Suppressor of Fused (SUFU) and with higher transcriptional activity (Ref. 25).
The subcellular localisation of GLI1 is tightly controlled. GLI1 nuclear localisation is observed upon HH stimulation and correlates with high transcriptional activity, whereas in absence of HH pathway activation GLI1 is retained in the cytoplasm and degraded by the proteasome. SUFU, one of the main negative regulators of HH signalling, interacts with GLI1 both at the N-terminal (amino acids 116-125) (Ref. 26) and at the C-terminal region (Refs 27, 28) and inhibits GLI1 both by retaining it in the cytoplasm and by repressing its transcriptional activity in the nucleus (Refs 29, 30).
GLI1 stability and proteasomal degradation is controlled by multiple factors. In absence of HH ligands, β-transducin repeat-containing protein (β-TrCP) E3 ubiquitin ligase recognises two sequences on GLI1 (degron N and C) and induces its proteasome-dependent degradation (Ref. The critical tumourigenic role of HH pathway is further highlighted by its activity in CSCs, through the subverted regulation of stemness genes, such as NANOG and SOX2, which are overexpressed in certain cancer types. More specifically, the HH pathway has been shown to directly regulate NANOG transcription through GLI1 and GLI2 in neural stem cells (Ref. 94) . In line with these findings, NANOG has been shown to act as a mediator of the HH-GLI signalling in regulating in vivo growth of glioblastoma CSCs (Ref. 95) . Similarly, HH-GLI signalling regulates the expression of SOX2 in neural stem cells and medulloblastoma (Refs 96, 97) . Recently, we showed that both GLI1 and GLI2 bind to SOX2 promoter in melanoma cells and that SOX2 function is required for HH-induced self-renewal of melanoma CSCs (Ref. 98) . Altogether, these findings suggest that aberrant HH signalling induces a number of stemness factors, that might play a critical role in the acquisition of a more undifferentiated and aggressive state through a process similar to reprogramming.
Activation of HH-GLI signalling in human cancers
The initial link between HH signalling and cancer came from the finding that loss of function mutations in PTCH1 gene are associated with a rare and hereditary form of BCC, basal cell nevus syndrome (BCNS) (also known as Gorlin syndrome) (Refs 59, 60, 99). BCNS is an autosomal dominant disorder with two distinct sets of phenotypes; increased risk of developing cancers such as BCC, medulloblastoma, rhabdomyosarcoma and meningioma, as well as developmental defects, including bifid ribs and ectopic calcifications (Ref. . BCNS patients are predisposed to BCC, MB and rhabdomyosarcoma, but they are not at increased risk to develop other cancer types, such as glioma, breast or prostate cancers. Genetic mouse models and identification of genetic mutations in BCC and MB have suggested that aberrant activation of HH signalling is required and sufficient for the development of these cancers. In other types of cancer activation of HH signalling might require additional alterations/ mutations in other signalling pathways to contribute to tumour development.
Glioma is the most frequent tumour of the central nervous system and can be classified into four grades, with glioblastoma multiforme (GBM) being the most aggressive. There are strong indications that the HH pathway is involved also in human breast cancer (BC), the leading cause of cancer death among women. High expression of components of HH pathway, including GLI1, is associated with a higher risk of recurrence after surgery and poorer prognosis (Refs 115, 116, 117). Consistently, transgenic mice that conditionally express GLI1 in the mammary epithelium develop mammary tumours (Ref. Ref. 188) . The activation of HH signalling in these diseases likely results from the integration of deregulated oncogenic inputs that contribute to the direct activation of the GLI proteins. Different haematological malignancies also show different modalities of HH signalling activation, which has been proposed to be paracrine mainly in CLL and plasma cell myeloma, both paracrine and autocrine in DLBCL and autocrine in ALL, AML and ALK+ALCL.
Modulation of HH-GLI signalling by oncogenic pathways
The activity of HH-GLI signalling observed in human cancer is the result of its functional interaction with other pathways and of the direct or indirect regulation of the final effectors of the HH signalling by oncogenes and tumour suppressors (Fig. 2) (Fig. 2b) . Likewise, transforming growth factor β (TGF-β) stimulation leads to a SMAD3-dependent induction of GLI2, which in turn increases GLI1 expression (Ref. 208 ). TGF-β also induces Kindlin-2, which increases GLI1 protein levels by inhibiting GSK3β. GLI1, in turn, represses Kindlin-2 creating a regulatory loop (Ref. 209) (Fig. 2b) . Activation of HH pathway in some tumours results from the increase of HH ligands. For instance, ERα pathway in gastric cancer (Ref. 210) or NF-kB in pancreatic cancer cells (Refs 211, 212) directly increase SHH expression, leading to enhanced proliferation and resistance to apoptosis. Direct induction of SHH is also mediated by p63β, p63γ and TAp73β, which bind to SHH promoter (Ref. 124) (Fig. 2b) .
Although HH signalling activation is regulated by many phosphorylation events, only few phosphatases have been described to modulate the pathway. In Drosophila PP4 and PP2A act as negative and positive modulators of HH signalling, acting at the level of Smo and Ci, respectively (Ref. 213) . Recently, the oncogenic wild-type p53-induced phosphatase 1 (WIP1) has been described to cooperate with SHH to enhance tumour formation in SHH-dependent medulloblastoma (Ref. 214) . Our group showed that WIP1 phosphatase activity enhances GLI1 function in melanoma by increasing GLI1 nuclear localisation, protein stability and transcriptional activity, whereas its inhibition reduces self-renewal and tumourigenicity of melanoma cells with activated HH signalling (Ref. 215) .
A negative reciprocal regulation is observed between GLI1 and the tumour suppressor p53. p53 inhibits the activity, nuclear localisation and protein levels of GLI1 in neural stem cells and glioblastoma cells (Ref. 216 (Fig. 2b) . In BC, high levels of liver kinase B1 (LKB1) are associated with low levels of HH signalling activation (Ref. 219) . Another suppressor of HH signalling is REN KCTD11 , which is often deleted in medulloblastoma and it has been shown to retain GLI1 in the cytoplasm, reducing its transcriptional activity (Ref. 63).
Regulation of HH signalling occurs also at epigenetic level. Menin, the gene mutated in multiple endocrine neoplasia type 1, recruits the protein arginine methyltransferase 5 (PRMT5) to growth arrest-specific 1 (Gas1) promoter. The consequent Gas1 repression prevents the binding of Shh to Ptch1, thus resulting in reduced HH pathway activity (Ref. 220 ). Different components of HH signalling are also targets of micro-RNAs (miR). miR-125b and miR-326, which target SMO, and miR-324-5p, which targets both SMO and GLI1, are downregulated in HH-driven MB and contribute to sustain tumour growth (Ref. 221) . In glioblastoma the miR-302-367 cluster inhibits clonogenicity and stemness of glioblastoma stem cells, through downregulation of CXCR4/SDF1 and consequent reduction of SHH, GLI1 and NANOG levels (Ref. 222 ).
Inhibitors of HH-GLI signalling
Current HH pathway antagonists can be classified according to what level of the pathway they modulate: (i) HH/PTCH interaction; (ii) SMO translocation and activation; (iii) GLI nuclear translocation and transcriptional activation (Fig. 3) . The use of SMO inhibitors has been associated with the acquisition of resistance to SMO inhibitors, mostly described in medulloblastoma, as a consequence of (i) mutations in human SMO (D473H) and the matching mutation in mouse (D477G), observed during vismodegib treatment In studies investigating systemic treatments with SMO inhibitors, a common set of adverse effects has been observed, including muscle spasms, loss of taste (dysgeusia), hair loss (alopecia), fatigue, nausea, diarrhoea, decreased appetite, weight loss and hyponatraemia (summarised in Table 1 ). It is likely that hair loss, altered taste and diarrhoea are directly related to the inhibition of the intended molecular target (SMO), since HH signalling is known to be active in hair follicle, taste buds and gastrointestinal tract (Refs 256, 257, 258) . Therefore, these effects are unlikely to be avoided by modifying the molecular structure of the agents. Possible strategies to lessen these effects would be to perform interval dosing of single agent or lower doses in combination with other agents (see later). Although most of the side effects of SMO inhibitors are mild to moderate (grade 1/2, Table 1 ), in some cases their severity has caused 50% of dropouts (Ref. 244) and raised concerns about long-term treatment in patients with BCC, typically a nonlife-threatening cancer. One way to avoid or reduce such effects in BCC might be to use these inhibitors topically, limiting systemic exposure. A study employing topical treatment of LDE-225 for 4 weeks documented an effective reduction in tumour size or clinical clearing that correlated with effective inhibition of HH signalling (Ref. 259) .
Acting at the level of SMO

Acting at the level of HH/PTCH interaction
Interference with the interaction between HH ligands and PTCH has been shown to attenuate HH signalling in experimental models. The monoclonal antibody 5E1 blocks the binding of HH ligands to PTCH1 with low nanomolar potency (Ref. 260 ). This antibody has been widely used in experimental studies to demonstrate HH dependency in tumour models, but it has not advanced to clinical settings. Recently, a novel neutralising antibody acting on SHH and IHH with low picomolar affinity has been reported (Ref. 261) . Moreover, two small molecules have been described; robotnikinin binds to and inhibits SHH protein (Ref. 262) , whereas RU-SKI, an inhibitor of HH acyltransferase, hampers SHH palmitoylation and blocks HH signalling (Ref. 263) .
Acting at the level of GLI
The development of molecules able to target directly the GLI, the final effectors of the HH signalling, would provide a good approach to block both canonical and non-canonical HH pathway activation and perhaps overcome anti-SMO drug resistance. Unfortunately, so far only few molecules acting on GLI proteins have been identified and their use is only limited to preclinical studies. A cell-based screening for inhibitors of GLI1-mediated transcription identified two structurally different compounds, GANT61 and GANT58. Both are capable of interfering with GLI1 and GLI2-mediated transcription and inhibit tumour cell growth in a Inhibition of BET bromodomain proteins has recently emerged as a novel strategy to target epigenetically the Hh pathway transcriptional output (Ref. 271 ). The BET bromodomain protein BRD4 is a critical regulator of GLI1 and GLI2 transcription through direct occupancy of their promoter. Interestingly, occupancy of GLI1 and GLI2 promoters by BRD4 and transcriptional activation at cancer-specific GLI promoterbinding sites are markedly inhibited by the BET inhibitor JQ1. In Ptch-deficient MB and BCC mouse models and patient-derived tumours with constitutive HH pathway activation, JQ1 decreases tumour cell proliferation and viability in vitro and in vivo, even in presence of genetic alterations conferring resistance to SMO inhibition (Ref. 271 ). These findings suggest that BET inhibition could be effective against tumour cells that evade SMO antagonists through mutation of SMO or amplification of GLI2 and MYCN, although the potential toxicities of BET inhibitors remain to be elucidated.
Acting on other proteins/pathways that modulate HH signalling
Other compounds might inhibit HH signalling by targeting proteins and/or pathways that modulate GLI transcription factors. For instance, forskolin inhibits HH signalling by activating PKA, which in turn is involved in the phosphorylation of GLI2/ GLI3, leading to their proteolytic processing into C-terminally truncated repressor forms (Ref. 
Evidence for rational combinations Combination of SMO inhibitors and other agents in preclinical studies
Support for combinatorial strategies is derived from the increasing amount of experimental data showing evidence of non-canonical HH signalling activation in tumours (summarised in Table 2 ). Combined inhibition of HH and MEK or AKT has been shown to yield additive/synergistic effects in reducing melanoma and cholangiocarcinoma cell proliferation in vitro (Refs 78, 275) . Combination of EGFR and SMO inhibitors has been described in several preclinical models. In pancreatic cancer cells, treatment with cyclopamine and EGFR inhibitor gefinitib decreased tumour growth rate and (Table 3) . Interestingly, the placebo group had a slightly better overall response than vismodegib-treated group (51% versus 46%), probably reflecting differences in safety and tolerability, as vismodegib-chemotherapy combination is less well tolerated compared with placebo-chemotherapy combination. In a pilot study, 25 patients with metastatic pancreatic adenocarcinoma were treated with a combination of vismodegib and gemcitabine. Vismodegib treatment for 3 weeks led to downregulation of GLI1 and PTCH1 in posttreatment biopsies in the majority of patients, without significant changes in the CSC compartment compared with baseline. However, vismodegib and gemcitabine were not better than gemcitabine alone in the treatment of metastatic pancreatic cancer (Ref. 299) .
Vismodegib is also being tested in combination with the mTOR inhibitor sirolimus, and in combination with the gonadotropin-releasing hormone agonist leuprolide or goserelin in metastatic pancreatic cancer and locally advanced prostate cancer, respectively (Table 3 ). In addition, clinical studies combining vismodegib with the Notch pathway inhibitor RO4929097 in advanced BC and sarcoma are ongoing. Multiple combination studies with sonidegib and BMS-833923 are either recruiting or ongoing. For instance, phase 1 studies of sonidegib in combination with PI3K inhibitor buparlisib in several types of advanced solid tumours, or in combination with BCR-ABL inhibitor nilotinib in patients with chronic myeloid leukaemia are recruiting (see Table 3 for details). Results from these clinical trials will address the applicability of SMO inhibitors in combination with other targets in multiple cancer types.
Perspectives
Over the last decade, knowledge of the HH-GLI signalling has greatly increased, enabling a better understanding of the interaction of the major oncogenic pathways during tumourigenesis. Despite these advances, our understanding of this signalling pathway is far from complete and many important questions remain to be answered. For example, which are the mechanisms of gene Tables  Table 1. Selected clinical trials of SMO inhibitors in cancer. Table 2 . Examples of preclinical combination studies of SMO inhibitors and other agents. 
